FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147609992> ?p ?o ?g. }

• W2147609992 endingPage "2224" @default.
• W2147609992 startingPage "2218" @default.
• W2147609992 abstract "Purpose We investigated the safety and efficacy (response rates, time to disease progression, survival) of trastuzumab, carboplatin, gemcitabine, and paclitaxel in advanced urothelial carcinoma patients and prospectively evaluated human epidermal growth factor receptor-2 (Her-2/neu) overexpression rates. Patients and Methods Advanced urothelial carcinoma patients were screened for Her-2/neu overexpression. Eligibility for therapy required human epidermal growth factor receptor-2 (Her-2/neu) overexpression by immunohistochemistry (IHC), gene amplification and/or elevated serum Her-2/neu, no prior chemotherapy for metastasis, and adequate organ function including a normal cardiac function. Treatment consisted of trastuzumab (T) 4 mg/kg loading dose followed by 2 mg/kg on days 1, 8, and 15; paclitaxel (P) 200 mg/m 2 on day 1; carboplatin (C; area under the curve, 5) on day 1; and gemcitabine (G) 800 mg/m 2 on days 1 and 8. The primary end point was cardiac toxicity. Results Fifty-seven (52.3%) of 109 registered patients were Her-2/neu positive, and 48.6% were positive by IHC. Her-2/neu–positive patients had more metastatic sites and visceral metastasis than did Her-2/neu negative patients. Forty-four of 57 Her-2/neu–positive patients were treated with TPCG. The median number of cycles was six (range, 1 to 12 cycles). The most common grade 3/4 toxicity was myelosuppression. Grade 3 sensory neuropathy occurred in 14% of patients, and 22.7% experienced grade 1 to 3 cardiac toxicity (grade 3, n = 2: one left ventricular dysfunction, one tachycardia). There were two therapy-related deaths. Thirty-one (70%) of 44 patients responded (five complete and 26 partial), and 25 (57%) of 44 were confirmed responses. Median time to progression and survival were 9.3 and 14.1 months, respectively. Conclusion We prospectively characterized Her-2/neu status in advanced urothelial carcinoma patients. TPCG is feasible; cardiac toxicity rates were higher than projected, but the majority were grade two or lower. Determining the true contribution of trastuzumab requires a randomized trial." @default.
• W2147609992 created "2016-06-24" @default.
• W2147609992 creator A5004935250 @default.
• W2147609992 creator A5028538472 @default.
• W2147609992 creator A5041126882 @default.
• W2147609992 creator A5050042851 @default.
• W2147609992 creator A5051935412 @default.
• W2147609992 creator A5059567824 @default.
• W2147609992 creator A5060006096 @default.
• W2147609992 creator A5063013010 @default.
• W2147609992 creator A5065161783 @default.
• W2147609992 creator A5073593424 @default.
• W2147609992 creator A5075799959 @default.
• W2147609992 creator A5089256383 @default.
• W2147609992 date "2007-06-01" @default.
• W2147609992 modified "2023-09-23" @default.
• W2147609992 title "Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/<i>neu</i>–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial" @default.
• W2147609992 cites W1965127349 @default.
• W2147609992 cites W1968007824 @default.
• W2147609992 cites W1971605007 @default.
• W2147609992 cites W1979620597 @default.
• W2147609992 cites W1992299982 @default.
• W2147609992 cites W1997936386 @default.
• W2147609992 cites W2001791004 @default.
• W2147609992 cites W2005084132 @default.
• W2147609992 cites W2030893402 @default.
• W2147609992 cites W2058210592 @default.
• W2147609992 cites W2059031630 @default.
• W2147609992 cites W2059963514 @default.
• W2147609992 cites W2060447952 @default.
• W2147609992 cites W2078504398 @default.
• W2147609992 cites W2095156669 @default.
• W2147609992 cites W2096813843 @default.
• W2147609992 cites W2099545363 @default.
• W2147609992 cites W2101562875 @default.
• W2147609992 cites W2103133513 @default.
• W2147609992 cites W2103257412 @default.
• W2147609992 cites W2108182027 @default.
• W2147609992 cites W2115759102 @default.
• W2147609992 cites W2137399990 @default.
• W2147609992 cites W2140074016 @default.
• W2147609992 cites W2141393790 @default.
• W2147609992 cites W2146384083 @default.
• W2147609992 cites W2149773268 @default.
• W2147609992 cites W2149908785 @default.
• W2147609992 cites W2151631271 @default.
• W2147609992 cites W2159459001 @default.
• W2147609992 cites W21899765 @default.
• W2147609992 cites W2199607744 @default.
• W2147609992 cites W2318605753 @default.
• W2147609992 cites W2596875443 @default.
• W2147609992 doi "https://doi.org/10.1200/jco.2006.08.0994" @default.
• W2147609992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17538166" @default.
• W2147609992 hasPublicationYear "2007" @default.
• W2147609992 type Work @default.
• W2147609992 sameAs 2147609992 @default.
• W2147609992 citedByCount "335" @default.
• W2147609992 countsByYear W21476099922012 @default.
• W2147609992 countsByYear W21476099922013 @default.
• W2147609992 countsByYear W21476099922014 @default.
• W2147609992 countsByYear W21476099922015 @default.
• W2147609992 countsByYear W21476099922016 @default.
• W2147609992 countsByYear W21476099922017 @default.
• W2147609992 countsByYear W21476099922018 @default.
• W2147609992 countsByYear W21476099922019 @default.
• W2147609992 countsByYear W21476099922020 @default.
• W2147609992 countsByYear W21476099922021 @default.
• W2147609992 countsByYear W21476099922022 @default.
• W2147609992 countsByYear W21476099922023 @default.
• W2147609992 crossrefType "journal-article" @default.
• W2147609992 hasAuthorship W2147609992A5004935250 @default.
• W2147609992 hasAuthorship W2147609992A5028538472 @default.
• W2147609992 hasAuthorship W2147609992A5041126882 @default.
• W2147609992 hasAuthorship W2147609992A5050042851 @default.
• W2147609992 hasAuthorship W2147609992A5051935412 @default.
• W2147609992 hasAuthorship W2147609992A5059567824 @default.
• W2147609992 hasAuthorship W2147609992A5060006096 @default.
• W2147609992 hasAuthorship W2147609992A5063013010 @default.
• W2147609992 hasAuthorship W2147609992A5065161783 @default.
• W2147609992 hasAuthorship W2147609992A5073593424 @default.
• W2147609992 hasAuthorship W2147609992A5075799959 @default.
• W2147609992 hasAuthorship W2147609992A5089256383 @default.
• W2147609992 hasBestOaLocation W21476099921 @default.
• W2147609992 hasConcept C121608353 @default.
• W2147609992 hasConcept C126322002 @default.
• W2147609992 hasConcept C143998085 @default.
• W2147609992 hasConcept C2776694085 @default.
• W2147609992 hasConcept C2777292972 @default.
• W2147609992 hasConcept C2778239845 @default.
• W2147609992 hasConcept C2779013556 @default.
• W2147609992 hasConcept C2779438470 @default.
• W2147609992 hasConcept C2779786085 @default.
• W2147609992 hasConcept C2780258809 @default.
• W2147609992 hasConcept C2781451048 @default.
• W2147609992 hasConcept C530470458 @default.
• W2147609992 hasConcept C71924100 @default.
• W2147609992 hasConceptScore W2147609992C121608353 @default.
• W2147609992 hasConceptScore W2147609992C126322002 @default.

• next